Invitation to Aerocrine’s presentation at the Small Cap Day on June 8 in Stockholm

Aerocrine AB (Nasdaq Stockholm: AERO) hereby invites investors, analysts and the media to join a live web cast from the Small Cap Day in Stockholm.

Scott Myers, CEO of Aerocrine, will inform about the Board’s recommendation to the shareholders to accept the public offer from Circassia and will do a company presentation of Aerocrine.

The Small Cap Day is arranged by the Swedish Shareholders’ Association and Redeye on June 8 at Sheraton Hotel in Stockholm. The Aerocrine presentation will start at 14.50 CET and can be watched on:

http://www.smabolagsdagen.net/live-sal-3/

For information about the public offer 2015, please visit www.aerocrine.com:

  • Board recommendation

  • Fairness opinion issued by Nordea

  • Information about the public offer

Welcome

Scott Myers, Chief Executive Officer, Aerocrine AB, Phone: +1 970 368 0336

Jenny Rosberg, IR/PR, ROPA, Phone +46 70 747 27 41

About Aerocrine

Aerocrine AB is a medical products company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in technology to monitor and manage airway inflammation, Aerocrine markets NIOX MINO® and NIOX VERO®. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the U.S., Germany, Switzerland and the U.K. Aerocrine shares were listed on the Nasdaq Stockholm Stock Exchange in 2007.

About Us

Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in the technology to monitor and manage airway inflammation, Aerocrine markets NIOX® Flex and NIOX MINO®. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June 2007.

Subscribe

Documents & Links